These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 4768915)

  • 1. A new leptospiral vaccine for use in man. I. Development of a vaccine from Leptospira grown on a chemically defined medium.
    Shenberg E; Torten M
    J Infect Dis; 1973 Nov; 128(5):642-6. PubMed ID: 4768915
    [No Abstract]   [Full Text] [Related]  

  • 2. Cellular and whole-culture bivalent leptospiral bacterins: safety and potency in guinea pigs and hamsters.
    Morsi HM; Shibley GP
    Am J Vet Res; 1973 Jan; 34(1):115-7. PubMed ID: 4683968
    [No Abstract]   [Full Text] [Related]  

  • 3. A new leptospiral vaccine for use in man. II. Clinical and serologic evaluation of a field trial with volunteers.
    Torten M; Shenberg E; Gerichter CB; Neuman P; Klingberg MA
    J Infect Dis; 1973 Nov; 128(5):647-51. PubMed ID: 4588702
    [No Abstract]   [Full Text] [Related]  

  • 4. Evaluation of a polyvalent leptospiral bacterin: safety in guinea pigs and potency in hamsters.
    Morsi HM; Shibley GP; Binkley FW
    Am J Vet Res; 1973 Jan; 34(1):113-4. PubMed ID: 4683967
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of vaccines prepared from leptospires grown in a serum medium and in a chemically defined medium.
    Kida H; Ishii T; Tsunehisa Y; Yamamoto S; Yanagawa R
    Zentralbl Bakteriol Orig A; 1977 May; 238(1):86-96. PubMed ID: 899375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of leptospiral vaccines grown in protein-free medium.
    Christopher WL; Adler B; Faine S
    J Med Microbiol; 1982 Nov; 15(4):493-501. PubMed ID: 7175917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ANTIGENICITY AND IMMUNOGENICITY OF LEPTOSPIRES GROWN IN CHEMICALLY CHARACTERIZED MEDIUM.
    STALHEIM OH; WILSON JB
    Am J Vet Res; 1964 Jul; 25():1277-80. PubMed ID: 14266881
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of Immunoprotection of Leptospira Recombinant Proteins with conventional vaccine in experimental animals.
    Parthiban M; Kumar SS; Balachandran C; Kumanan K; Aarthi KS; Nireesha G
    Indian J Exp Biol; 2015 Dec; 53(12):779-85. PubMed ID: 26742322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current status of leptospiral immunizing agents for use in swine.
    Huhn RG
    J Am Vet Med Assoc; 1972 Feb; 160(4):634-7. PubMed ID: 4113120
    [No Abstract]   [Full Text] [Related]  

  • 10. Leptospiral vaccines: immunogenicity of protein-free medium cultivated whole cell bacterins in swine.
    Bey RF; Johnson RC
    Am J Vet Res; 1983 Dec; 44(12):2299-301. PubMed ID: 6660619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of mechanisms of leptospiral hemolytic anemia.
    Decker MJ; Freeman MJ; Morter RL
    Am J Vet Res; 1970 May; 31(5):873-8. PubMed ID: 5445315
    [No Abstract]   [Full Text] [Related]  

  • 12. Reverse Vaccinology: An Approach for Identifying Leptospiral Vaccine Candidates.
    Dellagostin OA; Grassmann AA; Rizzi C; Schuch RA; Jorge S; Oliveira TL; McBride AJ; Hartwig DD
    Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28098813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA prime-protein boost based vaccination with a conserved region of leptospiral immunoglobulin-like A and B proteins enhances protection against leptospirosis.
    Forster KM; Hartwig DD; Oliveira TL; Bacelo KL; Schuch R; Amaral MG; Dellagostin OA
    Mem Inst Oswaldo Cruz; 2015 Dec; 110(8):989-95. PubMed ID: 26676320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Product-specific validation of a serological potency test for release of Leptospira vaccines in the European Union.
    Stirling C; Novokova V
    Biologicals; 2013 Sep; 41(5):330-1. PubMed ID: 23849308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. USDA regulatory guidelines and practices for veterinary Leptospira vaccine potency testing.
    Srinivas GB; Walker A; Rippke B
    Biologicals; 2013 Sep; 41(5):298-302. PubMed ID: 23838570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of leptospiral agglutinins in patients. A ten year experience.
    PIKE RM; SCHULZE ML
    J Lab Clin Med; 1961 Feb; 57():223-9. PubMed ID: 13735701
    [No Abstract]   [Full Text] [Related]  

  • 17. Antigenic potential of a recombinant polyvalent DNA vaccine against pathogenic leptospiral infection.
    Garba B; Bahaman AR; Zakaria Z; Bejo SK; Mutalib AR; Bande F; Suleiman N
    Microb Pathog; 2018 Nov; 124():136-144. PubMed ID: 30138761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric epitope vaccine against Leptospira interrogans infection and induced specific immunity in guinea pigs.
    Lin X; Xiao G; Luo D; Kong L; Chen X; Sun D; Yan J
    BMC Microbiol; 2016 Oct; 16(1):241. PubMed ID: 27737644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenic properties of a leptospiral outer envelope bacterin in hamsters and foxes.
    Glosser JW; Johnson RC; Sulzer CR; Auran NE
    Am J Vet Res; 1974 May; 35(5):681-4. PubMed ID: 4830438
    [No Abstract]   [Full Text] [Related]  

  • 20. Development and validation of a serological potency test for the release of Leptospira vaccines--requirements in the European Union.
    Balks E; Gyra H; Kobe B; Cussler K; Werner E
    Biologicals; 2013 Sep; 41(5):325-9. PubMed ID: 23911253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.